Table 1. Patient and Treatment Characteristics in the Retrospective Cohort Data Set.
| Characteristic | EBRT duration, No. (%) | EBRT+BT duration, No. (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | <6 mo | 6-<18 mo | ≥18 mo | 0 | <6 mo | 6-<18 mo | ≥18 mo | |
| No. (%) | 478 (26.1) | 100 (5.4) | 318 (17.4) | 931 (51.0) | 165 (14.9) | 243 (21.9) | 297 (26.8) | 403 (36.4) |
| Follow-up, median (IQR), y | 6.6 (3.7-10.2) | 4.9 (3.2-8.0) | 5.6 (3.2-8.2) | 6.8 (4.3-9.3) | 4.5 (2.3-7.8) | 4.6 (2.2-8.5) | 7 (4.3-9.3) | 8.5 (6.5-11.1) |
| Age at treatment, median (IQR), y | 70 (63.3-75.0) | 72.9 (66.3-76.0) | 73 (65.9-77.0) | 70 (64.0-75.0) | 67 (60.0-72.0) | 68 (62.5-74.0) | 67.2 (61.4-73.4) | 67 (62.7-72.0) |
| cT category | ||||||||
| T1, T2 | 79 (16.6) | 21 (21.4) | 56 (17.8) | 297 (32.4) | 19 (11.5) | 68 (28.1) | 89 (30.1) | 218 (54.2) |
| T3, T4 | 398 (83.4) | 77 (78.6) | 258 (82.2) | 621 (67.6) | 146 (88.5) | 174 (71.9) | 207 (69.9) | 184 (45.8) |
| iPSA, median (IQR), ng/mL | 14.7 (6.9-27.9) | 13 (7.0-22.4) | 12.6 (6.8-23.3) | 12.3 (6.7-26.4) | 9.3 (5.9-20.4) | 13.1 (7.7-25.2) | 12.1 (6.6-23.4) | 23 (11.9-33.4) |
| iPSA >20 ng/mL | ||||||||
| No | 272 (56.9) | 63 (63.6) | 214 (67.5) | 623 (67.1) | 117 (70.9) | 155 (64.0) | 199 (67.0) | 160 (39.7) |
| Yes | 206 (43.1) | 36 (36.4) | 103 (32.5) | 305 (32.9) | 48 (29.1) | 87 (36.0) | 98 (33.0) | 243 (60.3) |
| Gleason grade group | ||||||||
| 1 | 41 (8.6) | 11 (11 .0) |
12 (3.8) | 32 (3.4) | 25 (15.2) | 19 (7.9) | 17 (5.8) | 54 (13.8) |
| 2 | 65 (13.7) | 12 (12.0) | 40 (12.6) | 82 (8.8) | 19 (11.5) | 30 (12.4) | 22 (7.5) | 39 (9.9) |
| 3 | 46 (9.7) | 10 (10.0) | 26 (8.2) | 72 (7.7) | 11 (6.7) | 26 (10.7) | 46 (15.6) | 106 (27.0) |
| 4 | 193 (40.5) | 43 (43.0) | 178 (56.0) | 513 (55.1) | 85 (51.5) | 112 (46.3) | 120 (40.7) | 111 (28.3) |
| 5 | 131 (27.5) | 24 (24.0) | 62 (19.5) | 232 (24.9) | 25 (15.2) | 55 (22.7) | 90 (30.5) | 82 (20.9) |
Abbreviations: EBRT, external beam radiotherapy; EBRT+BT, external beam radiotherapy plus brachytherapy boost; iPSA, initial prostate-specific antigen.